5AM Ventures V, L.P. sold $867k of TRDA
owner at Entrada Therapeutics, Inc.. 125,000 shares at an average of $6.93, traded Jun 27, 2025, filed Jul 1, 2025.
Score components
- +12Role10% owner
- +23Trade size$867k at market
- 0Share of holdings soldSold 3.8% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-018822, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 27, 2025 | SOpen-market sale Common Stock | -55,735 | $6.91 | $385k | 3,220,287 | Jul 1, 2025 |
| Jun 27, 2025 | SOpen-market sale Common Stockindirect: By 5AM Opportunities I, L.P. | -19,265 | $6.91 | $133k | 1,113,092 | Jul 1, 2025 |
| Jun 30, 2025 | SOpen-market sale Common Stock | -18,578 | $6.81 | $127k | 3,201,709 | Jul 1, 2025 |
| Jun 30, 2025 | SOpen-market sale Common Stockindirect: By 5AM Opportunities I, L.P. | -6,422 | $6.81 | $44k | 1,106,670 | Jul 1, 2025 |
| Jul 1, 2025 | SOpen-market sale Common Stock | -18,578 | $7.12 | $132k | 3,183,131 | Jul 1, 2025 |
| Jul 1, 2025 | SOpen-market sale Common Stockindirect: By 5AM Opportunities I, L.P. | -6,422 | $7.12 | $46k | 1,100,248 | Jul 1, 2025 |
Related signals
Other insiders at Entrada Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | Entrada Therapeutics, Inc. | MPM BioVentures 2014, L.P. owner | $1.9M 259,837 shares | -6% | |
| 45Moderate | Entrada Therapeutics, Inc. | Mpm Bioventures 2018, L.p. owner | $1.9M 259,837 shares | -6% | |
| 40Moderate | Entrada Therapeutics, Inc. | MPM BioVentures 2014, L.P. owner | $617k 86,482 shares | -2% | |
| 40Moderate | Entrada Therapeutics, Inc. | Mpm Bioventures 2018, L.p. owner | $617k 86,482 shares | -2% | |
| 36Weak | TRDAbuy Entrada Therapeutics, Inc. | Baker Bros. Advisors LP owner | $262k 28,867 shares | +8% | |
| 26Weak | Entrada Therapeutics, Inc. | Kory James Wentworth Chief Financial Officer | $89k 8,910 shares | -7% | |
| 52Moderate | Entrada Therapeutics, Inc. | 5AM Ventures V, L.P. owner | $1.8M 200,000 shares | -6% | |
| 55Moderate | Entrada Therapeutics, Inc. | Kush Parmar director, owner | $1.8M 200,000 shares | -6% | |
| 46Moderate | TRDAbuy Entrada Therapeutics, Inc. | Baker Bros. Advisors LP owner | $1.4M 178,044 shares | +49% | |
| 32Weak | Entrada Therapeutics, Inc. | 5AM Ventures V, L.P. owner | $203k 27,000 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.